Merck & Company, Inc. (MRK) Analyst Ratings & Price Targets

Merck & Company, Inc.

MRK · NYSE

Analyst Consensus

Buy

24 analysts

0 Bearish2 Neutral1 Bullish

$144

Current

$145

Low

$165

Average

$145

High

Average target implies +14.35% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Buy across 24 analysts, but its stated target figures are internally inconsistent: a $145 low and $145 high cannot contain a $165 mean. Other listed snapshots differ: Investing.com reports a $158.56 average and a $105–$186 range, while TipRanks gives a $161.19 average and MarketBeat $153.12. The most bullish named target in the supplied evidence is Guggenheim’s $171, raised from $170 while retaining Buy after Q3; the least bullish is Wolfe Research’s $135 target, reported as a January action and therefore not a comparable weekly revision. Guggenheim is the only explicit recent revision: upward by $1. The substantive debate is whether KEYTRUDA and newer medicines can offset patent and generic pressure, including Gardasil weakness.

Symbol: MRK
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world - and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Key Issues

Bullish view

KEYTRUDA demand and faster-growing newer medicines are supporting sales and helped Merck raise its 2026 outlook.

Bearish view

Generic and patent pressures remain a looming risk, and the evidence does not establish that newer products can fully replace revenue exposed to those pressures.

Analyst Consensus

See all

Buy

24 analysts

0 Bearish2 Neutral1 Bullish

$144

Current

$145

Low

$165

Average

$145

High

Average target implies +14.35% versus the current price.

Earnings History

BeatMissNo estimate

Rating Actions

3 firms captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
RBC Capital	—	Sector Perform Maintained rating; lowered price target	$145from $150	+0.5%	Oct 12, 2026	Open the report this row came from
RBC Capital	—	Hold Reiterated	—	—	Sep 30, 2026	Open the report this row came from
HSBC	—	Unrated Maintained rating and raised price target	$172from $150	+19.2%	Sep 9, 2026	Open the report this row came from
Leerink Partners	—	Outperform Maintained rating and raised price target	$161from $127	+11.6%	Sep 9, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Merck & Company, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Peers

Rating Actions

Research Reports

Covering Firms